Combination of dopamine transporter and D2 receptor SPECT in the diagnostic evaluation of PD, MSA, and PSP
Identifieur interne : 001923 ( Main/Exploration ); précédent : 001922; suivant : 001924Combination of dopamine transporter and D2 receptor SPECT in the diagnostic evaluation of PD, MSA, and PSP
Auteurs : Yun J. Kim [Canada] ; Masanori Ichise [Canada] ; James R. Ballinger [Canada] ; Douglas Vines [Canada] ; Sean S. Erami [Canada] ; Tatsuro Tatschida [Canada] ; Anthony E. Lang [Canada]Source :
- Movement Disorders [ 0885-3185 ] ; 2002-03.
English descriptors
Abstract
It is often difficult to differentiate clinically between Parkinson's disease (PD), multiple system atrophy (MSA), and progressive supranuclear palsy (PSP).The objective of this work was to investigate whether combined pre‐ and postsynaptic dopaminergic single photon emission computed tomography (SPECT) scanning can reliably demonstrate changes in the nigrostriatal dopaminergic system and help differentiate between normal controls, PD, MSA, and PSP patients. We performed SPECT evaluation of the dopamine transporter (DAT) and dopamine D2 receptors (D2). SPECT scans using [123I]β‐CIT (for DAT) and [123I]IBF (for D2) were performed in 18 patients with PD (12 dopa‐naïve and 6 on levodopa and/or dopamine agonists), 7 with MSA of the striatonigral degeneration type, 6 with PSP, and 29 normal controls. Antiparkinsonian drugs were withheld for at least 12 hours before the scans. DAT and D2 binding potentials (Rv = V3/V2) were measured for caudate, anterior, and posterior putamen on the sides ipsilateral and contralateral to the worst motor symptoms. DAT binding in the posterior putamen was markedly reduced in all patients. However, D2 binding in posterior putamen was significantly increased in dopa‐untreated PD, being greater than the normal range in 4 of 12 (33%), and it was significantly reduced in MSA, being below the normal range in 5 of 7 (71%). None of the patients with PD showed reduced D2 binding below the normal range in posterior putamen. The degree of DAT binding could not discriminate between the patient groups. The ratio of posterior putamen to caudate percentage D2 Rv compared with the controls showed an opposite pattern between PD or PSP and MSA; the caudate was greater in 16 of 18 with PD and 6 of 6 with PSP, whereas caudate was less in 5 of 7 with MSA. These findings suggest that DAT SPECT may be useful in differentiating parkinsonism from controls and D2 SPECT in further differentiating MSA from Parkinson's disease and possibly PSP. © 2002 Movement Disorder Society.
Url:
DOI: 10.1002/mds.10042
Affiliations:
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Combination of dopamine transporter and D2 receptor SPECT in the diagnostic evaluation of PD, MSA, and PSP</title><author><name sortKey="Kim, Yun J" sort="Kim, Yun J" uniqKey="Kim Y" first="Yun J." last="Kim">Yun J. Kim</name></author><author><name sortKey="Ichise, Masanori" sort="Ichise, Masanori" uniqKey="Ichise M" first="Masanori" last="Ichise">Masanori Ichise</name></author><author><name sortKey="Ballinger, James R" sort="Ballinger, James R" uniqKey="Ballinger J" first="James R." last="Ballinger">James R. Ballinger</name></author><author><name sortKey="Vines, Douglas" sort="Vines, Douglas" uniqKey="Vines D" first="Douglas" last="Vines">Douglas Vines</name></author><author><name sortKey="Erami, Sean S" sort="Erami, Sean S" uniqKey="Erami S" first="Sean S." last="Erami">Sean S. Erami</name></author><author><name sortKey="Tatschida, Tatsuro" sort="Tatschida, Tatsuro" uniqKey="Tatschida T" first="Tatsuro" last="Tatschida">Tatsuro Tatschida</name></author><author><name sortKey="Lang, Anthony E" sort="Lang, Anthony E" uniqKey="Lang A" first="Anthony E." last="Lang">Anthony E. Lang</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:603E6C60F12D49771F6B7FCECCBB581E49C099BF</idno><date when="2002" year="2002">2002</date><idno type="doi">10.1002/mds.10042</idno><idno type="url">https://api.istex.fr/document/603E6C60F12D49771F6B7FCECCBB581E49C099BF/fulltext/pdf</idno><idno type="wicri:Area/Main/Corpus">002C12</idno><idno type="wicri:Area/Main/Curation">002843</idno><idno type="wicri:Area/Main/Exploration">001923</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Combination of dopamine transporter and D2 receptor SPECT in the diagnostic evaluation of PD, MSA, and PSP</title><author><name sortKey="Kim, Yun J" sort="Kim, Yun J" uniqKey="Kim Y" first="Yun J." last="Kim">Yun J. Kim</name><affiliation wicri:level="1"><country xml:lang="fr">Canada</country><wicri:regionArea>Morton & Gloria Shulman Movement Disorders Center and the Division of Neurology (Department of Medicine), The Toronto Western Hospital, Toronto, Ontario</wicri:regionArea><wicri:noRegion>Ontario</wicri:noRegion></affiliation><affiliation wicri:level="4"><country xml:lang="fr">Canada</country><wicri:regionArea>University of Toronto, Toronto, Ontario</wicri:regionArea><orgName type="university">Université de Toronto</orgName><placeName><settlement type="city">Toronto</settlement><region type="state">Ontario</region></placeName></affiliation></author><author><name sortKey="Ichise, Masanori" sort="Ichise, Masanori" uniqKey="Ichise M" first="Masanori" last="Ichise">Masanori Ichise</name><affiliation wicri:level="1"><country xml:lang="fr">Canada</country><wicri:regionArea>Division of Nuclear Medicine, Mount Sinai Hospital Site of University Medical Imaging Center, Toronto, Ontario</wicri:regionArea><wicri:noRegion>Ontario</wicri:noRegion></affiliation><affiliation wicri:level="4"><country xml:lang="fr">Canada</country><wicri:regionArea>University of Toronto, Toronto, Ontario</wicri:regionArea><orgName type="university">Université de Toronto</orgName><placeName><settlement type="city">Toronto</settlement><region type="state">Ontario</region></placeName></affiliation></author><author><name sortKey="Ballinger, James R" sort="Ballinger, James R" uniqKey="Ballinger J" first="James R." last="Ballinger">James R. Ballinger</name><affiliation wicri:level="1"><country xml:lang="fr">Canada</country><wicri:regionArea>Division of Nuclear Medicine, Mount Sinai Hospital Site of University Medical Imaging Center, Toronto, Ontario</wicri:regionArea><wicri:noRegion>Ontario</wicri:noRegion></affiliation><affiliation wicri:level="4"><country xml:lang="fr">Canada</country><wicri:regionArea>University of Toronto, Toronto, Ontario</wicri:regionArea><orgName type="university">Université de Toronto</orgName><placeName><settlement type="city">Toronto</settlement><region type="state">Ontario</region></placeName></affiliation></author><author><name sortKey="Vines, Douglas" sort="Vines, Douglas" uniqKey="Vines D" first="Douglas" last="Vines">Douglas Vines</name><affiliation wicri:level="1"><country xml:lang="fr">Canada</country><wicri:regionArea>Division of Nuclear Medicine, Mount Sinai Hospital Site of University Medical Imaging Center, Toronto, Ontario</wicri:regionArea><wicri:noRegion>Ontario</wicri:noRegion></affiliation><affiliation wicri:level="4"><country xml:lang="fr">Canada</country><wicri:regionArea>University of Toronto, Toronto, Ontario</wicri:regionArea><orgName type="university">Université de Toronto</orgName><placeName><settlement type="city">Toronto</settlement><region type="state">Ontario</region></placeName></affiliation></author><author><name sortKey="Erami, Sean S" sort="Erami, Sean S" uniqKey="Erami S" first="Sean S." last="Erami">Sean S. Erami</name><affiliation wicri:level="1"><country xml:lang="fr">Canada</country><wicri:regionArea>Division of Nuclear Medicine, Mount Sinai Hospital Site of University Medical Imaging Center, Toronto, Ontario</wicri:regionArea><wicri:noRegion>Ontario</wicri:noRegion></affiliation><affiliation wicri:level="4"><country xml:lang="fr">Canada</country><wicri:regionArea>University of Toronto, Toronto, Ontario</wicri:regionArea><orgName type="university">Université de Toronto</orgName><placeName><settlement type="city">Toronto</settlement><region type="state">Ontario</region></placeName></affiliation></author><author><name sortKey="Tatschida, Tatsuro" sort="Tatschida, Tatsuro" uniqKey="Tatschida T" first="Tatsuro" last="Tatschida">Tatsuro Tatschida</name><affiliation wicri:level="1"><country xml:lang="fr">Canada</country><wicri:regionArea>Division of Nuclear Medicine, Mount Sinai Hospital Site of University Medical Imaging Center, Toronto, Ontario</wicri:regionArea><wicri:noRegion>Ontario</wicri:noRegion></affiliation><affiliation wicri:level="4"><country xml:lang="fr">Canada</country><wicri:regionArea>University of Toronto, Toronto, Ontario</wicri:regionArea><orgName type="university">Université de Toronto</orgName><placeName><settlement type="city">Toronto</settlement><region type="state">Ontario</region></placeName></affiliation></author><author><name sortKey="Lang, Anthony E" sort="Lang, Anthony E" uniqKey="Lang A" first="Anthony E." last="Lang">Anthony E. Lang</name><affiliation wicri:level="1"><country xml:lang="fr">Canada</country><wicri:regionArea>Morton & Gloria Shulman Movement Disorders Center and the Division of Neurology (Department of Medicine), The Toronto Western Hospital, Toronto, Ontario</wicri:regionArea><wicri:noRegion>Ontario</wicri:noRegion></affiliation><affiliation wicri:level="4"><country xml:lang="fr">Canada</country><wicri:regionArea>University of Toronto, Toronto, Ontario</wicri:regionArea><orgName type="university">Université de Toronto</orgName><placeName><settlement type="city">Toronto</settlement><region type="state">Ontario</region></placeName></affiliation></author></analytic><monogr></monogr><series><title level="j">Movement Disorders</title><title level="j" type="sub">Official Journal of the Movement Disorder Society</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="ISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>New York</pubPlace><date type="published" when="2002-03">2002-03</date><biblScope unit="volume">17</biblScope><biblScope unit="issue">2</biblScope><biblScope unit="page" from="303">303</biblScope><biblScope unit="page" to="312">312</biblScope></imprint><idno type="ISSN">0885-3185</idno></series><idno type="istex">603E6C60F12D49771F6B7FCECCBB581E49C099BF</idno><idno type="DOI">10.1002/mds.10042</idno><idno type="ArticleID">MDS10042</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>PSP, MSA</term><term>Parkinson's disease</term><term>SPECT</term><term>dopamine D2 receptors</term><term>dopamine transporter</term><term>imaging</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">It is often difficult to differentiate clinically between Parkinson's disease (PD), multiple system atrophy (MSA), and progressive supranuclear palsy (PSP).The objective of this work was to investigate whether combined pre‐ and postsynaptic dopaminergic single photon emission computed tomography (SPECT) scanning can reliably demonstrate changes in the nigrostriatal dopaminergic system and help differentiate between normal controls, PD, MSA, and PSP patients. We performed SPECT evaluation of the dopamine transporter (DAT) and dopamine D2 receptors (D2). SPECT scans using [123I]β‐CIT (for DAT) and [123I]IBF (for D2) were performed in 18 patients with PD (12 dopa‐naïve and 6 on levodopa and/or dopamine agonists), 7 with MSA of the striatonigral degeneration type, 6 with PSP, and 29 normal controls. Antiparkinsonian drugs were withheld for at least 12 hours before the scans. DAT and D2 binding potentials (Rv = V3/V2) were measured for caudate, anterior, and posterior putamen on the sides ipsilateral and contralateral to the worst motor symptoms. DAT binding in the posterior putamen was markedly reduced in all patients. However, D2 binding in posterior putamen was significantly increased in dopa‐untreated PD, being greater than the normal range in 4 of 12 (33%), and it was significantly reduced in MSA, being below the normal range in 5 of 7 (71%). None of the patients with PD showed reduced D2 binding below the normal range in posterior putamen. The degree of DAT binding could not discriminate between the patient groups. The ratio of posterior putamen to caudate percentage D2 Rv compared with the controls showed an opposite pattern between PD or PSP and MSA; the caudate was greater in 16 of 18 with PD and 6 of 6 with PSP, whereas caudate was less in 5 of 7 with MSA. These findings suggest that DAT SPECT may be useful in differentiating parkinsonism from controls and D2 SPECT in further differentiating MSA from Parkinson's disease and possibly PSP. © 2002 Movement Disorder Society.</div></front></TEI><affiliations><list><country><li>Canada</li></country><region><li>Ontario</li></region><settlement><li>Toronto</li></settlement><orgName><li>Université de Toronto</li></orgName></list><tree><country name="Canada"><noRegion><name sortKey="Kim, Yun J" sort="Kim, Yun J" uniqKey="Kim Y" first="Yun J." last="Kim">Yun J. Kim</name></noRegion><name sortKey="Ballinger, James R" sort="Ballinger, James R" uniqKey="Ballinger J" first="James R." last="Ballinger">James R. Ballinger</name><name sortKey="Ballinger, James R" sort="Ballinger, James R" uniqKey="Ballinger J" first="James R." last="Ballinger">James R. Ballinger</name><name sortKey="Erami, Sean S" sort="Erami, Sean S" uniqKey="Erami S" first="Sean S." last="Erami">Sean S. Erami</name><name sortKey="Erami, Sean S" sort="Erami, Sean S" uniqKey="Erami S" first="Sean S." last="Erami">Sean S. Erami</name><name sortKey="Ichise, Masanori" sort="Ichise, Masanori" uniqKey="Ichise M" first="Masanori" last="Ichise">Masanori Ichise</name><name sortKey="Ichise, Masanori" sort="Ichise, Masanori" uniqKey="Ichise M" first="Masanori" last="Ichise">Masanori Ichise</name><name sortKey="Kim, Yun J" sort="Kim, Yun J" uniqKey="Kim Y" first="Yun J." last="Kim">Yun J. Kim</name><name sortKey="Lang, Anthony E" sort="Lang, Anthony E" uniqKey="Lang A" first="Anthony E." last="Lang">Anthony E. Lang</name><name sortKey="Lang, Anthony E" sort="Lang, Anthony E" uniqKey="Lang A" first="Anthony E." last="Lang">Anthony E. Lang</name><name sortKey="Tatschida, Tatsuro" sort="Tatschida, Tatsuro" uniqKey="Tatschida T" first="Tatsuro" last="Tatschida">Tatsuro Tatschida</name><name sortKey="Tatschida, Tatsuro" sort="Tatschida, Tatsuro" uniqKey="Tatschida T" first="Tatsuro" last="Tatschida">Tatsuro Tatschida</name><name sortKey="Vines, Douglas" sort="Vines, Douglas" uniqKey="Vines D" first="Douglas" last="Vines">Douglas Vines</name><name sortKey="Vines, Douglas" sort="Vines, Douglas" uniqKey="Vines D" first="Douglas" last="Vines">Douglas Vines</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001923 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 001923 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:603E6C60F12D49771F6B7FCECCBB581E49C099BF
|texte= Combination of dopamine transporter and D2 receptor SPECT in the diagnostic evaluation of PD, MSA, and PSP
}}
| This area was generated with Dilib version V0.6.23. |  |